Výsledky vyhledávání - "Gregory S, Cameron"

Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)

Autor: Neil J. Korman, Gregory S Cameron, Susan Ball, Lotus Mallbris, Carle Paul, L. Zhang, Kristian Reich, Andrew Blauvelt, Christopher E.M. Griffiths, Kim A. Papp, J. Erickson, Craig L. Leonardi, Mamitaro Ohtsuki

Publikováno v: Papp, K A, Leonardi, C L, Blauvelt, A, Reich, K, Korman, N J, Ohtsuki, M, Paul, C, Ball, S, Cameron, G S, Erickson, J, Zhang, L, Mallbris, L & Griffiths, C E M 2017, ' Ixekizumab treatment for psoriasis : Integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3) ', The British journal of dermatology . https://doi.org/10.1111/bjd.16050

BACKGROUND: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A, is approved for the treatment of moderate-to-severe psoriasis.OBJECTIVES: This analysis represents an overview of the efficacy outcomes from th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d6ce0ee68d9648dcf5a768e3076d9bf
https://doi.org/10.1111/bjd.16050

Zobrazit plný text záznamu

Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: Subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1)

Autor: Shinichi Imafuku, Fangyi Zhao, Atsushi Nishikawa, Hitoe Torisu-Itakura, Gregory S Cameron

Publikováno v: The Journal of Dermatology

The present study describes a subgroup analysis of 33 Japanese patients participating in UNCOVER‐1, an international, placebo‐controlled, phase 3 study of ixekizumab in patients with moderate‐to‐severe psoriasis. Patients were randomized to a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7feaabac93c1ea5290f73e31683f7eb
https://doi.org/10.1111/1346-8138.13927

Zobrazit plný text záznamu

A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis

Autor: Gregory S Cameron, Craig L. Leonardi, Michael P. Heffernan, J. Erickson, Daniel K. Braun, Andrew Blauvelt, Mark Lebwohl, Kenneth B. Gordon

Publikováno v: Journal of the American Academy of Dermatology. 71:1176-1182

Background Patients with moderate to severe plaque psoriasis demonstrated positive responses to ixekizumab, an anti-interleukin-17A monoclonal antibody, in a phase-II, randomized, placebo-controlled trial. Objective We sought to evaluate long-term ef

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6513fe58a231a4f89dcc58af33944136
https://doi.org/10.1016/j.jaad.2014.07.048

Zobrazit plný text záznamu

Population exposure-response model to support dosing evaluation of ixekizumab in patients with chronic plaque psoriasis

Autor: Subhashis Banerjee, Gregory S Cameron, Julie Satterwhite, Siak‐Leng Choi, Lai‐San Tham, Cheng‐Cai Tang

Publikováno v: The Journal of Clinical Pharmacology. 54:1117-1124

Ixekizumab (LY2439821), a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody that selectively binds and neutralizes interleukin (IL) 17A has demonstrated efficacy in the treatment of psoriasis. A population pharmacokinetics-pharmacodyna

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6846bbaf1c4d84b4fe726adf7228b5ab
https://doi.org/10.1002/jcph.312

Zobrazit plný text záznamu

Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis

Autor: Subhashis Banerjee, Kenneth B. Gordon, D. Shrom, P. Wang, Baojin Zhu, Emily Edson-Heredia, Gregory S Cameron, Wei Shen, J. Erickson

Publikováno v: British Journal of Dermatology. 169:1337-1341

Summary Background Early identification of responsiveness to biologic treatments in psoriasis has significant clinical and economic implications. Objectives To evaluate whether early clinical improvements in Psoriasis Area and Severity Index (PASI) s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e6dc448375bd8b9987fc4583ceb0de5
https://doi.org/10.1111/bjd.12610

Zobrazit plný text záznamu

Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)

Autor: Hidehisa, Saeki, Hidemi, Nakagawa, Ko, Nakajo, Taeko, Ishii, Yoji, Morisaki, Takehiro, Aoki, Gregory S, Cameron, Olawale O, Osuntokun, Keiichi, Yamanaka

Publikováno v: The Journal of Dermatology

Psoriasis, a chronic, immune‐mediated skin disease characterized by red, scaly plaques, affects approximately 0.3% of the population in Japan. The aim of this open‐label study was to evaluate the long‐term efficacy and safety of ixekizumab, a h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c44e469ae27513007b8c9f5e2f79211
https://pubmed.ncbi.nlm.nih.gov/27726163

Zobrazit plný text záznamu

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

Autor: Emily Edson-Heredia, Robert Matheson, Subhashis Banerjee, Craig L. Leonardi, Claus Zachariae, Linda Li, Gregory S Cameron, Daniel K. Braun

Publikováno v: New England Journal of Medicine. 366:1190-1199

At 12 weeks, the percentage of patients with a reduction in the PASI score by at least 75% was significantly greater with ixekizumab (except with the lowest, 10-mg dose) ― 150 mg (82.1%), 75 mg (82.8%), and 25 mg (76.7%) ― than with placebo (7.7%

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a41706eec05530cdcfe1848393646b13
https://doi.org/10.1056/nejmoa1109997

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání